{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.2","upperLimit":"67.1","value":"54.6"},{"groupId":"OG001","lowerLimit":"42.3","upperLimit":"67.6","value":"55.2"},{"groupId":"OG002","lowerLimit":"63.1","upperLimit":"84.1","value":"74.3"},{"groupId":"OG003","lowerLimit":"65.9","upperLimit":"86.7","value":"77.2"},{"groupId":"OG004","lowerLimit":"32.9","upperLimit":"51.6","value":"42.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"98"}],"units":"Participants"}],"description":"ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \\* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.","dispersionType":"95% Confidence Interval","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received study drug in Part A. Participants who had missing components of the ACR20 index at Week 12 had these components imputed by LOCF.","reportingStatus":"POSTED","timeFrame":"Baseline through Week 12","title":"Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}